Celularity, Inc.

ACTIVE

新泽西州摩里斯县, New Jersey, United Stateswww.celularity.comPublic225 employeesEstablished: 2017-09-01$66.2M

Also known as:

celularity incorporated

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2017

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

64.7%

Phase 2

35.3%

Trial Status Distribution

Completed

29.4%

Terminated

52.9%

Unknown

5.9%

Withdrawn

11.8%

Clinical Trials

Trials sponsored by this organization (17)

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1

Terminated

interventional

Apr 20221 participant

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Phase 1

Terminated

interventional

Oct 20203 participants

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Phase 1

Completed

interventional

Jan 201715 participants

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Phase 1

Terminated

interventional

Jul 201610 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations

Celularity, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (17)

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Approvals

News